Kinnon joins PredictImmune having spent over 20 years in a number of executive positions in the US and is anticipated to drive the company's next phase of development, commercialisation and expansion.
Following a career start as an analytical chemist at Smithkline French and Beckman Research, a predecessor company of GlaxoSmithKline, Kinnon went on to hold leadership positions with Transgenomic, ZyGEM, Life Technologies, Guava Technologies, and Cellomics.
PredictImmune is developing tools for guiding treatment options in immune-mediated inflammatory diseases with the first product addressing inflammatory bowel disease.
Based on research at Cambridge University, the company is developing a simple lab test, using a small blood sample, which accurately identifies patients at diagnosis who are at risk of experiencing severe, relapsing disease.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer